Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Flunisolide→

Flunisolide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3385-03-3
Molecular formula
C24H31FO6
Molecular weight
434.5 g/mol
Drug class
Synthetic glucocorticoidinhaled and intranasal corticosteroid anti-inflammatory agent
Mechanism of action
Activates intracellular glucocorticoid receptors and regulates transcription of inflammatory mediators, reducing airway and nasal mucosal inflammation, oedema and mucus production.
Indications / reported uses
  • Maintenance treatment of asthma with inhaled formulations; not for relief of acute bronchospasm
  • Treatment of nasal symptoms associated with seasonal or perennial allergic rhinitis with authorised intranasal formulations

Sources: US DailyMed — Flunisolide nasal spray · NLM MeSH — Flunisolide · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Flunisolide Environmental Risk Assessment (ERA) (the Flunisolide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.